Therapeutic Glaucoma

Nicox’s NCX 470 Dolomites Phase 2 results published in Journal of Glaucoma

NCX 470 is currently enrolling patients in two multi-regional Phase 3 glaucoma clinical trials, Mont Blanc and Denali. The objective of these two trials is to demonstrate statistically superior IOP lowering of once daily dosed NCX 470

Travoprost intracameral implant shows efficacy in topical form

Device demonstrates potential as a durable, sustained-release glaucoma therapy

iSTAR Medical continues market expansion with first MINIject® surgeries in the UK

The company announced the expansion of its commercial rollout of its MIGS implant to the UK